BPH

Editor's Choice

Post-PVP urinary incontinence associated with age, prostate size

In the minority of patients who experience postoperative urinary incontinence following photoselective vaporization of the prostate for BPH, the more severe symptoms are associated with age and preoperative prostate size.

LATEST ARTICLES

New Tool: Rx Adherence Predictor

Now you can determine in advance the likelihood of a patient filling and staying on their medications. This tool can support your ability to prioritize and target patients who may benefit from counseling about the importance of maintaining your prescribed drug regimen.

Dutasteride and tamsulosin (Jalyn): A combination of dutasteride, a 5α-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist for the treatment of symptomatic benign prostatic hyperplasia

New combination: Dutasteride and tamsulosin (Jalyn) was approved by FDA for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

Physician’s Focus: Botox for Urologic Conditions

Although botulinum neurotoxins are currently being evaluated for urologic disorders and are not yet FDA-approved, results from a 2005 study show that Botulinum toxin Type A can significantly decrease signs and symptoms of urinary incontinence. ModernMedicine provides several thought-provoking articles on this topic.

New prostate treatments reflect expanding patient demographic as population ages

As baby boomers age, the pool of patients needing prostate treatment is expanding dramatically. With more patients asking questions, pharmacists need to be ready with answers.

FDA approves once-daily BPH treatment

Watson Pharmaceuticals has received FDA approval to market silodosin (Rapaflo), an alpha-blocker for the treatment of BPH signs and symptoms.